{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T08:41:20Z","timestamp":1791103280431,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.semarthrit.2013.01.003","type":"journal-article","created":{"date-parts":[[2013,2,20]],"date-time":"2013-02-20T16:41:25Z","timestamp":1361378485000},"page":"113-118","source":"Crossref","is-referenced-by-count":57,"title":["Tocilizumab for polymyalgia rheumatica: Report of two cases and review of the literature"],"prefix":"10.1016","volume":"43","author":[{"given":"Pierluigi","family":"Macchioni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Boiardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagrazia","family":"Catanoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia","family":"Pulsatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Pipitone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Meliconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Salvarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.semarthrit.2013.01.003_bib1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1056\/NEJMra011913","article-title":"Polymyalgia rheumatica and giant-cell arteritis","volume":"347","author":"Salvarani","year":"2002","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.semarthrit.2013.01.003_bib2","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/art.1780360913","article-title":"Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis","volume":"36","author":"Roche","year":"1993","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2013.01.003_bib3","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/archinte.159.6.577","article-title":"Corticosteroid requirements in polymyalgia rheumatica","volume":"159","author":"Weyand","year":"1999","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2013.01.003_bib4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/art.20901","article-title":"Acute-phase reactants and the risk of relapse\/recurrence in polymyalgia rheumatica: a prospective followup study","volume":"53","author":"Salvarani","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2013.01.003_bib5","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/ard.2008.103663","article-title":"Circulating cytokines in active polymyalgia rheumatica","volume":"69","author":"Alvarez-Rodr\u00edguez","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.semarthrit.2013.01.003_bib6","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/art.23924","article-title":"Serum interleukin-6 receptor in polymyalgia rheumatica: a potential marker of relapse\/recurrence risk","volume":"59","author":"Pulsatelli","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.semarthrit.2013.01.003_bib7","first-page":"703","article-title":"Relationship between interleukin 6 promoter polymorphism at position -174, IL-6 serum levels, and the risk of relapse\/recurrence in polymyalgia rheumatica","volume":"33","author":"Boiardi","year":"2006","journal-title":"J Rheumatol"},{"issue":"9617","key":"10.1016\/j.semarthrit.2013.01.003_bib8","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.semarthrit.2013.01.003_bib9","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard.2008.105197","article-title":"Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study","volume":"69","author":"Jones","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2013.01.003_bib10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/annrheumdis-2011-201282","article-title":"Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)","volume":"72","author":"Dougados","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 3","key":"10.1016\/j.semarthrit.2013.01.003_bib11","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/annrheumdis-2012-eular.1963","article-title":"Tocilizumab monotherapy is superior to adalimumab monotherapy in reducing disease activity in patients with rheumatoid arthritis: 24-week data from the phase 4 ADACTA trial","volume":"71","author":"Gabay","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2013.01.003_bib12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ard.2008.088179","article-title":"Tocilizumab for multirefractory adult-onset Still's disease","volume":"68","author":"De Bandt","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.semarthrit.2013.01.003_bib13","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1136\/ard.2010.149351","article-title":"Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis","volume":"70","author":"Beyer","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.semarthrit.2013.01.003_bib14","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.3899\/jrheum.110496","article-title":"Interleukin 6 blockade as steroid-sparing treatment for 2 patients with giant cell arteritis","volume":"38","author":"Sciascia","year":"2011","journal-title":"J Rheumatol"},{"issue":"1 Suppl. 70","key":"10.1016\/j.semarthrit.2013.01.003_bib15","first-page":"S90","article-title":"Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-\u03b1 blockers","volume":"30","author":"Salvarani","year":"2012","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2013.01.003_bib16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/rheumatology\/ker296","article-title":"Tocilizumab: a novel therapy for patients with large-vessel vasculitis","volume":"51","author":"Salvarani","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.semarthrit.2013.01.003_bib17","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jbspin.2011.11.008","article-title":"Efficacy of tocilizumab in refractory giant cell arteritis","volume":"79","author":"Vinit","year":"2012","journal-title":"Joint Bone Spine"},{"issue":"8","key":"10.1016\/j.semarthrit.2013.01.003_bib18","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s10067-012-2007-3","article-title":"Ultrasonographic resolution of the vessel wall oedema with modest clinical improvement in a large-vessel vasculitis patient treated with tocilizumab","volume":"31","author":"Besada","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2013.01.003_bib19","first-page":"w13156","article-title":"Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series","volume":"141","author":"Seitz","year":"2011","journal-title":"Swiss Med Wkly"},{"issue":"11","key":"10.1016\/j.semarthrit.2013.01.003_bib20","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1002\/acr.21750","article-title":"Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica","volume":"64","author":"Unizony","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2013.01.003_bib21","unstructured":"Pazzola G, Padovano I, Boiardi L, Versari A, Pipitone N, Catanoso M, et al. Tocilizumab in glucorticoid na\u00efve large vessel vasculitis. Clin Exp Rheum 2013 [Epub ahead of print]."},{"issue":"2","key":"10.1016\/j.semarthrit.2013.01.003_bib22","first-page":"123","article-title":"The Italian version of the functional disability index of the health assessment questionnaire: a reliable instrument for multicenter studies on rheumatoid arthritis","volume":"11","author":"Ranza","year":"1993","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"10.1016\/j.semarthrit.2013.01.003_bib23","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1136\/ard.2003.011379","article-title":"A disease activity score for polymyalgia rheumartica","volume":"63","author":"Leeb","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.semarthrit.2013.01.003_bib24","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/art.22771","article-title":"The polymyalgia rheumatica activity score in daily use: proposal for a definition of remission","volume":"57","author":"Leeb","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.semarthrit.2013.01.003_bib25","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1093\/rheumatology\/kep286","article-title":"Longitudinal examination with shoulder ultrasound of patients with polymyalgia rheumatica","volume":"48","author":"Macchioni","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.semarthrit.2013.01.003_bib26","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3899\/jrheum.091185","article-title":"Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica","volume":"37","author":"Hagihara","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2013.01.003_bib27","doi-asserted-by":"crossref","unstructured":"Christidis D, Jain S, Das Gupta B. Successful use of tocilizumab in polymyalgic onset biopsy positive GCA with large vessel involvement. BMJ Case Rep 2011;2011. pii: bcr0420114135.","DOI":"10.1136\/bcr.04.2011.4135"},{"issue":"10","key":"10.1016\/j.semarthrit.2013.01.003_bib28","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1002\/art.1780401022","article-title":"Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica","volume":"40","author":"Gabriel","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.semarthrit.2013.01.003_bib29","doi-asserted-by":"crossref","first-page":"493","DOI":"10.7326\/0003-4819-141-7-200410050-00005","article-title":"Systemic Vasculitis Study Group of the Italian Society for Rheumatology. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial","volume":"141","author":"Caporali","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2013.01.003_bib30","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1136\/ard.55.4.218","article-title":"Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?","volume":"55","author":"van der Veen","year":"1996","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2013.01.003_bib31","first-page":"760","article-title":"Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study","volume":"30","author":"Salvarani","year":"2003","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2013.01.003_bib32","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1002\/art.23095","article-title":"Treatment of refractory polymyalgia rheumatica with etanercept: an open pilot study","volume":"57","author":"Catanoso","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.semarthrit.2013.01.003_bib33","doi-asserted-by":"crossref","first-page":"631","DOI":"10.7326\/0003-4819-146-9-200705010-00005","article-title":"Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial","volume":"146","author":"Salvarani","year":"2007","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.semarthrit.2013.01.003_bib34","doi-asserted-by":"crossref","first-page":"R176","DOI":"10.1186\/ar3140","article-title":"Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial","volume":"12","author":"Kreiner","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.semarthrit.2013.01.003_bib35","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1053\/j.gastro.2004.01.012","article-title":"A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease","volume":"126","author":"Ito","year":"2004","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.semarthrit.2013.01.003_bib36","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017213000097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017213000097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T19:32:43Z","timestamp":1562700763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017213000097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0049017213000097"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2013.01.003","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}